Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millennium initiates Velcade retreatment trial
The trial, named EVEREST, is a multi-center clinical trial that will assess the efficacy of retreatment with Velcade (bortezomib) for injection in terms of best confirmed M-protein response.
The trial, named EVEREST, is a multi-center clinical trial that will assess the efficacy of retreatment with Velcade (bortezomib) for injection in terms of best confirmed M-protein response.
According to the World Health Organization (WHO), there have been 55 cases with 42 laboratory-confirmed deaths from the H5N1 avian influenza virus between January 28, 2004 and February
The study, for which Perlegen was awarded a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to provide greater insight into the
On November 23, 2004, Inyx announced it was awarded an exclusive five-year contract to produce NovaDel’s nitroglycerin lingual spray for the treatment of acute angina, the first of
The court order filing seeks to block the potential launch of generic versions of Niaspan 500mg, 750mg and 1,000mg extended-release tablets (Niacin extended-release tablets) following final FDA approval.
The orphan drug designation follows adoption of a positive opinion by the Committee for Orphan Medicinal Products of the European Agency for the Evaluation of Medicinal Products. Orphan
Pharming will now conduct clinical trials to assess the safety and efficacy of its recombinant human C1 inhibitor (rhC1INH) to treat acute attacks of hereditary angioedema (HAE), a
Results from one phase II study conducted in Spain showed that long-term Remune treatment was effective in delaying virologic failure during antiretroviral treatment interruption. The second phase II
As a result, Avanir, through its subsidiary, holds the exclusive worldwide marketing rights to Neurodex for five indications under a royalty-bearing license with the owner of the underlying
The $230 million cash-for-stock transaction is expected to close in the second quarter of 2005, subject to customary closing conditions and regulatory approvals. Following the acquisition, Johnson &